home / stock / catb / catb quote
Last: | $8.54 |
---|---|
Change Percent: | -6.97% |
Open: | $9.21 |
Close: | $8.54 |
High: | $9.21 |
Low: | $8.46 |
Volume: | 98,765 |
Last Trade Date Time: | 09/08/2021 04:56:30 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.54 | $9.21 | $8.54 | $9.21 | $8.46 | 98,765 | 09-08-2021 |
$9.18 | $9.57 | $9.18 | $9.68 | $8.95 | 94,097 | 09-07-2021 |
$9.53 | $10.07 | $9.53 | $10.18 | $9.44 | 81,959 | 09-06-2021 |
$9.53 | $10.07 | $9.53 | $10.18 | $9.44 | 81,446 | 09-03-2021 |
$10.06 | $9.6 | $10.06 | $10.26 | $9.6 | 109,511 | 09-02-2021 |
$9.41 | $10 | $9.41 | $10.1899 | $9.37 | 83,367 | 09-01-2021 |
$9.97 | $9.38 | $9.97 | $10.09 | $9.38 | 171,508 | 08-31-2021 |
$9.43 | $9.45 | $9.43 | $9.48 | $9.31 | 50,071 | 08-30-2021 |
$9.36 | $9.07 | $9.36 | $9.63 | $9.0622 | 155,511 | 08-27-2021 |
$9.07 | $9.2 | $9.07 | $9.4999 | $9.05 | 124,016 | 08-26-2021 |
$9.26 | $9.37 | $9.26 | $9.6 | $9.01 | 316,123 | 08-25-2021 |
$8.72 | $8.74 | $8.72 | $8.77 | $8.28 | 154,362 | 08-24-2021 |
$8.8 | $7.28 | $8.8 | $8.97 | $7.213 | 585,840 | 08-23-2021 |
$7.58 | $6.45 | $7.58 | $8.57 | $6.31 | 5,341,744 | 08-20-2021 |
$1.22 | $1.31 | $1.22 | $1.32 | $1.2 | 747,794 | 08-19-2021 |
$1.3 | $1.3 | $1.3 | $1.34 | $1.27 | 318,411 | 08-18-2021 |
$1.32 | $1.33 | $1.32 | $1.33 | $1.26 | 307,718 | 08-17-2021 |
$1.32 | $1.33 | $1.32 | $1.3582 | $1.29 | 403,340 | 08-16-2021 |
$1.34 | $1.35 | $1.34 | $1.39 | $1.32 | 265,440 | 08-13-2021 |
$1.36 | $1.43 | $1.36 | $1.43 | $1.35 | 526,457 | 08-12-2021 |
News, Short Squeeze, Breakout and More Instantly...
Catabasis Pharmaceuticals Inc. Company Name:
CATB Stock Symbol:
NASDAQ Market:
Catabasis Pharmaceuticals Inc. Website:
-- Astria Reflects Company’s Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin Trading Under New Ticker Symbol ATXS on September 9 -- Cataba...
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “We are focused on advancing the development of our lead program, QLS-215, as a differe...